TriangleNCT00352105 · OUTCOME
Number of Participants With No Distant Metastatic Disease at 1 Year
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- NUMBER
- Unit
- participants
- Interval / dispersion
- Not reported
- Time frame
- 1 year
What was measured
1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.
Analysis population: 5 early deaths were not evaluable
Groups in this outcome
5-FU, Cisplatin, Radiation and Iressa
Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.
| Group | Source count |
|---|---|
| 5-FU, Cisplatin, Radiation and Iressa | 55 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| 5-FU, Cisplatin, Radiation and Iressa | 54 | 2 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 2
- value
- 54
- denoms
- counts
- group Id
- OG000
- value
- 55
- units
- Participants
- description
- 1-year distant metastatic disease control in patients with locally advanced squamous cell head and neck cancer. Distant disease means that cancer came back in sites outside of the head and neck.
- groups
- description
- Patients undergo hyperfractionated radiotherapy twice daily, 5 days a week, beginning on day 1 and continuing for 6 weeks. Patients also receive fluorouracil IN continuously over 96 hrs. and cisplatin IV continuously over 96 hrs. on days 1-3 and 22-25 and oral gefitinib beginning once daily on day 1 and continuing for up to 2 years in the absence of disease progression or unacceptable toxicity.
- id
- OG000
- title
- 5-FU, Cisplatin, Radiation and Iressa
- param Type
- NUMBER
- population Description
- 5 early deaths were not evaluable
- reporting Status
- POSTED
- time Frame
- 1 year
- title
- Number of Participants With No Distant Metastatic Disease at 1 Year
- type
- PRIMARY
- unit Of Measure
- participants
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice